07:44 AM EDT, 06/23/2022 (MT Newswires) -- Amryt Pharma (AMYT) said Thursday that the European Commission approved Filsuvez in the European Union for the treatment of partial thickness wounds related to dystrophic and junctional epidermolysis bullosa in patients age 6 months and older.

Epidermolysis bullosa is a rare genetic skin disorder in young children and adults for which there has been no approved treatment as of yet, the company noted.

The approval of Filsuvez is backed by phase 3 data from the company's EASE trial with patients across 58 sites in 28 countries.

Amryt's shares were up almost 5% in premarket trading on Thursday morning.

Price: 7.19, Change: +0.34, Percent Change: +4.96